Ontario Securities Commission

Early Warning Report Issued Pursuant to National Instrument 62-103 – Disposition of Securities of Clip Money Inc.

Retrieved on: 
Friday, March 8, 2024
PALM, Transaction, TSX Venture Exchange, Telephone, Ontario Securities Commission, Early warning, CAD, Indian stock exchange, Legislation, KOAT, Security (finance)

Prior to the Transactions, KOAT owned an aggregate of 14,914,292 Common Shares, representing approximately 14.21% of the Company’s current issued and outstanding Common Shares.

Key Points: 
  • Prior to the Transactions, KOAT owned an aggregate of 14,914,292 Common Shares, representing approximately 14.21% of the Company’s current issued and outstanding Common Shares.
  • Following the Transactions, KOAT owns 10,564,660 Common Shares, representing approximately 10.07% of the Company’s current issued and outstanding Common Shares.
  • A copy of such report may also be obtained by contacting Mr. Daren Trousdell (by e-mail at [email protected] or by telephone at 561-515-9010).
  • KOAT is located at 736 Ibis Way, North Palm Beach, FL 33408 and the Company’s head office is located at 96 Riverdale Ave, Ottawa, Ontario K1S 1R2.

Magna Announces Senior Notes Offering

Retrieved on: 
Tuesday, March 5, 2024
MGA, Prospectus, TSX, EDGAR, Sale, Ontario Securities Commission, BofA Securities, Security (finance), Citigroup, BNP Paribas

AURORA, Ontario, March 05, 2024 (GLOBE NEWSWIRE) -- Magna International Inc. (TSX: MG; NYSE: MGA) today announced that it has entered into an underwriting agreement in respect of the offering of U.S.$400 million aggregate principal amount of senior unsecured notes due 2029 (the “notes”).

Key Points: 
  • AURORA, Ontario, March 05, 2024 (GLOBE NEWSWIRE) -- Magna International Inc. (TSX: MG; NYSE: MGA) today announced that it has entered into an underwriting agreement in respect of the offering of U.S.$400 million aggregate principal amount of senior unsecured notes due 2029 (the “notes”).
  • Magna intends to use the net proceeds from the offering of notes for general corporate purposes, which may include the repayment of its existing indebtedness.
  • The offering of notes is expected to close on March 14, 2024, subject to customary closing conditions.
  • The offering of notes may be made only by means of a prospectus supplement and accompanying prospectus.

OBSI announces new board members

Retrieved on: 
Friday, March 1, 2024
University of Toronto, Bank of Montreal, Trillium, University, University of British Columbia, Osgoode Hall Law School, Associate, Woman, Royal Bank of Canada, Fellow, Ethics, Bank, CFA, Information, Community, Retail, Royal Bank, Financial regulation, Toronto Life, Capital market, Regulation, HSBC Bank Canada, Ontario Securities Commission, Business, Ombudsman, CAIA, Walter, Knowledge, Commission, Commissioner, Insurance, Complaint, Central bank, Government, OSC, Distinguishing

TORONTO, March 01, 2024 (GLOBE NEWSWIRE) -- The Board of Directors for the Ombudsman for Banking Services and Investments (OBSI) is pleased to announce four appointments to the board:

Key Points: 
  • TORONTO, March 01, 2024 (GLOBE NEWSWIRE) -- The Board of Directors for the Ombudsman for Banking Services and Investments (OBSI) is pleased to announce four appointments to the board:
    Mary Condon has joined the board as a Consumer Interest Director.
  • Previously, she was a board member of the Capital Markets Authority Implementation Organization, and Commissioner and board member of the Ontario Securities Commission (OSC), where she was also a Vice-Chair.
  • All directors have a fiduciary duty to OBSI and do not advocate for or represent any outside interest while engaged in OBSI governance.
  • If a consumer has a complaint against an OBSI participating bank or investment firm that they are not able to resolve with the bank or firm, OBSI will investigate at no cost to the consumer.

BioVaxys Technology Corp. Granted Voluntary Management Cease Trade Order

Retrieved on: 
Friday, March 8, 2024
CFO, Acquisition, Certification, Fortnight, Requirement, News, File, FRA, IAS, Ontario Securities Commission, OSC, DMCL, Documentation, IMV, National Policy, National instrument, IAS 10

VANCOUVER, BC, March 8, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") today announced that the Ontario Securities Commission (the "OSC"), as the Company's principal regulator, on February 29, 2024, granted the Company's previously announced application for the imposition of a management cease trade order under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203").

Key Points: 
  • VANCOUVER, BC, March 8, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") today announced that the Ontario Securities Commission (the "OSC"), as the Company's principal regulator, on February 29, 2024, granted the Company's previously announced application for the imposition of a management cease trade order under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203").
  • The management cease trade order is to remain in place until two full business days after the Company files the Required Reports and restricts all trading by James Passin, director, CEO and CFO of the Company in securities of the Company.
  • The Company applied for a management cease trade order as an alternative to the imposition by the OSC of a full cease trade order.
  • The management cease trade order prevents the officers and/or directors named in the order from trading in the Company's securities but does not affect the ability of other shareholders, including the public, to trade in securities of the Company.

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

Retrieved on: 
Thursday, March 7, 2024
Requirement, FRA, Ontario Securities Commission, National instrument, Bank statement

VANCOUVER, BC, March 7, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024, (the "MCTO") by its principal regulator, the Ontario Securities Commission (the "OSC"), under National Policy 12-203 - Management Cease Trade Orders ("NP 12-203"), following the Company's announcement on February 21, 2024 (the "Default Announcement") that it was unable to file its audited annual  financial statements for the year ended October 31, 2023, its management's discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023 and related filings (collectively the "Required Filings").

Key Points: 
  • VANCOUVER, BC, March 7, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024, (the "MCTO") by its principal regulator, the Ontario Securities Commission (the "OSC"), under National Policy 12-203 - Management Cease Trade Orders ("NP 12-203"), following the Company's announcement on February 21, 2024 (the "Default Announcement") that it was unable to file its audited annual  financial statements for the year ended October 31, 2023, its management's discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023 and related filings (collectively the "Required Filings").
  • Under National Instrument 51-102, the Required Filings were required to be made not later than February 28, 2024 (the " Filing Deadline").
  • The Company still expects to file the Required Filings by March 30, 2024.
  • There are no material changes to the information contained in the Default Announcement.

BioVaxys Technology Corp. Granted Voluntary Management Cease Trade Order

Retrieved on: 
Wednesday, March 6, 2024
CFO, Acquisition, Certification, Fortnight, Requirement, News, File, FRA, IAS, Ontario Securities Commission, OSC, DMCL, Documentation, IMV, National Policy, National instrument, IAS 10

VANCOUVER, BC, March 6, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") today announced that the Ontario Securities Commission (the "OSC"), as the Company's principal regulator, on February 29, 2024, granted the Company's previously announced application for the imposition of a management cease trade order under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203").

Key Points: 
  • VANCOUVER, BC, March 6, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") today announced that the Ontario Securities Commission (the "OSC"), as the Company's principal regulator, on February 29, 2024, granted the Company's previously announced application for the imposition of a management cease trade order under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203").
  • The management cease trade order is to remain in place until two full business days after the Company files the Required Reports and restricts all trading by James Passin, director, CEO and CFO of the Company in securities of the Company.
  • The Company applied for a management cease trade order as an alternative to the imposition by the OSC of a full cease trade order.
  • The management cease trade order prevents the officers and/or directors named in the order from trading in the Company's securities but does not affect the ability of other shareholders, including the public, to trade in securities of the Company.

BioVaxys Technology Corp. Granted Voluntary Management Cease Trade Order

Retrieved on: 
Friday, March 8, 2024
CFO, Acquisition, Certification, Fortnight, Requirement, News, File, FRA, IAS, Ontario Securities Commission, OSC, DMCL, Documentation, IMV, National Policy, National instrument, IAS 10

VANCOUVER, BC, March 8, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") today announced that the Ontario Securities Commission (the "OSC"), as the Company's principal regulator, on February 29, 2024, granted the Company's previously announced application for the imposition of a management cease trade order under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203").

Key Points: 
  • VANCOUVER, BC, March 8, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") today announced that the Ontario Securities Commission (the "OSC"), as the Company's principal regulator, on February 29, 2024, granted the Company's previously announced application for the imposition of a management cease trade order under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203").
  • The management cease trade order is to remain in place until two full business days after the Company files the Required Reports and restricts all trading by James Passin, director, CEO and CFO of the Company in securities of the Company.
  • The Company applied for a management cease trade order as an alternative to the imposition by the OSC of a full cease trade order.
  • The management cease trade order prevents the officers and/or directors named in the order from trading in the Company's securities but does not affect the ability of other shareholders, including the public, to trade in securities of the Company.

OSC awards $1.5 million to whistleblower

Retrieved on: 
Tuesday, February 27, 2024
CAD, Algorithm, Confidentiality, Person, Artificial intelligence, Ontario Securities Commission, OSC

TORONTO, Feb. 27, 2024 /CNW/ - The Ontario Securities Commission (OSC) issued an award of CAD $1,500,000 to a whistleblower who provided information which allowed the OSC to act swiftly to protect investors from harm.

Key Points: 
  • TORONTO, Feb. 27, 2024 /CNW/ - The Ontario Securities Commission (OSC) issued an award of CAD $1,500,000 to a whistleblower who provided information which allowed the OSC to act swiftly to protect investors from harm.
  • The whistleblower was an insider and submitted very specific and discrete non-public information to the OSC that broadened the scope of an existing investigation and contributed to the successful enforcement action.
  • "The whistleblower had access to valuable information regarding early-stage misconduct that was critical to our ability to quickly respond and protect investors from further harm," said Jeff Kehoe, Director of Enforcement at the OSC.
  • The OSC Whistleblower Program offers protections for individuals who come forward with information about potential violations of Ontario securities law and awards up to $5 million for tips that lead to successful enforcement action.

Annual Financial Statements Update for the Year Ended October 31, 2023

Retrieved on: 
Wednesday, February 21, 2024
Acquisition, Person, Requirement, News, File, FRA, IAS, Ontario Securities Commission, OSC, DMCL, Documentation, National Policy, National instrument, Policy, DPX, IAS 10, Bank statement, Audit

Under National Instrument 51-102, the Required Filings are required to be made not later than February 28, 2024 (the " Filing Deadline").

Key Points: 
  • Under National Instrument 51-102, the Required Filings are required to be made not later than February 28, 2024 (the " Filing Deadline").
  • The Company believes that this acquisition constitutes a major purchase of assets that must be reported in its financial statement in accordance with IAS 10.
  • The Company continues to work to complete the Company's annual financial statements, and expects to file the Required Filings by March 30, 2024, and will issue a news release once the Required Filings have been filed.
  • The Company's auditors have also made significant efforts to complete its audit of the annual financial statements.

European High Growth Opportunities Securitization Fund Comments on Press Release Issued by Tony G Co-Investment Holdings Ltd.

Retrieved on: 
Monday, February 12, 2024
Professional Services, Finance, Court, Fund, Ontario Securities Commission, Security (finance)

The Fund would like to notify shareholders of the Company that the Fund rejects the purported share issuance and continues to allege that the Company is bound by, and in breach of, its obligations under the Debenture.

Key Points: 
  • The Fund would like to notify shareholders of the Company that the Fund rejects the purported share issuance and continues to allege that the Company is bound by, and in breach of, its obligations under the Debenture.
  • The Fund continues to pursue its claim against the Company which will be heard by the Ontario Superior Court of Justice (the “Court”) on November 22, 2024.
  • The Fund reminds both management and the board of directors of the Company that they are bound by their fiduciary obligations to the Company and all stakeholders.
  • The Fund denies the validity of the share issuance to the Fund and will continue to seek recourse against the Company through its litigation in the Court.